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Abstract
Background: Radiotherapy (RT) and androgen-deprivation therapy (ADT) are standard treatments for advanced
prostate cancer (PC). Tumor vascularization is recognized as an important physiological feature likely to impact on
both RT and ADT response, and this study therefore aimed to characterize the vascular responses to RT and ADT
in experimental PC.
Methods: Using mice implanted with CWR22 PC xenografts, vascular responses to RT and ADT by castration were
visualized in vivo by DCE MRI, before contrast-enhancement curves were analyzed both semi-quantitatively and by
pharmacokinetic modeling. Extracted image parameters were correlated to the results from ex vivo quantitative
fluorescent immunohistochemical analysis (qIHC) of tumor vascularization (9 F1), perfusion (Hoechst 33342), and
hypoxia (pimonidazole), performed on tissue sections made from tumors excised directly after DCE MRI.
Results: Compared to untreated (Ctrl) tumors, an improved and highly functional vascularization was detected in
androgen-deprived (AD) tumors, reflected by increases in DCE MRI parameters and by increased number of vessels
(VN), vessel density (VD), and vessel area fraction (VF) from qIHC. Although total hypoxic fractions (HF) did not
change, estimated acute hypoxia scores (AHS) – the proportion of hypoxia staining within 50 μm from perfusion
staining – were increased in AD tumors compared to in Ctrl tumors. Five to six months after ADT renewed
castration-resistant (CR) tumor growth appeared with an even further enhanced tumor vascularization. Compared
to the large vascular changes induced by ADT, RT induced minor vascular changes. Correlating DCE MRI and qIHC
parameters unveiled the semi-quantitative parameters area under curve (AUC) from initial time-points to strongly
correlate with VD and VF, whereas estimation of vessel size (VS) by DCE MRI required pharmacokinetic modeling.
HF was not correlated to any DCE MRI parameter, however, AHS may be estimated after pharmacokinetic modeling.
Interestingly, such modeling also detected tumor necrosis very strongly.
Conclusions: DCE MRI reliably allows non-invasive assessment of tumors’ vascular function. The findings of
increased tumor vascularization after ADT encourage further studies into whether these changes are beneficial for
combined RT, or if treatment with anti-angiogenic therapy may be a strategy to improve the therapeutic efficacy
of ADT in advanced PC.
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Background
Androgens play key regulatory functions in prostate
cancer (PC) growth and proliferation. Androgen-deprivation
therapy (ADT) is established as an integral component
of contemporary management of advanced PC, providing
reduction of androgen-sensitive tumor cells and symp-
tomatic relief for the patients [1]. However, the lack
of durable remission indicates that current ADT strat-
egies are suboptimal, or that successful treatment out-
come may require ADT to be combined with other
therapeutic interventions. Specifically, the combination
of ADT with radiotherapy (RT) has proven efficacious
[2,3], yet the optimal timing of RT in relation to ADT
remains unclear.
Tumor vascularization is an important physiological
feature of tumor tissue, influencing both RT and ADT
response. Adequate tumor oxygenation results in enhanced
radical formation following RT, inducing irreversible
DNA damage and subsequent tumor cell death [4].
Well-vascularized tumors are more likely to be well
oxygenated, in contrast to poorly vascularized tumors
often suffering from tumor hypoxia, reducing the efficacy
of combined treatments, including RT. Moreover, ADT
affects tumor vascularization by its direct influence
on androgen-sensitive, endothelial cells. Although the
endothelial cells express androgen receptors providing
paracrine signaling and vascular support facilitating
recurrent growth, the role of androgens in regulation of
angiogenesis is still not fully understood [5,6]. Further,
most investigations have focused on the initial vascular
response following ADT, typically from a few hours up
to one week. The more long-term effects of ADT on
tumor vasculature may be equally or more important in
understanding PC progression, and for selection of com-
bined treatments.
Quantitative dynamic contrast-enhanced magnetic res-
onance imaging (DCE MRI) is a promising non-invasive
imaging modality for assessing tumor vacularization
and treatment responses [7]. Conventional extracellular
contrast agents rapidly distribute throughout the blood
plasma and extravasate into the extracellular extravascu-
lar space (EES) after being intravenously (i.v.) injected.
These agents affect the tissues’ relaxation rates, causing
increased signal intensity on T1-weighted MR images.
The signal intensity changes versus time reflect vascular
features and may be analyzed directly using semi-
quantitative approaches or quantitatively by pharmacokinetic
models. Extracted image parameters enable estimation of
the tumors’ vascular characteristics and their angiogenic
responses to therapeutic interventions, potentially also
serving as indirect non-invasive biomarkers of tumor
hypoxia. However, the use of DCE MRI parameters is
dependent on correct tumor physiological interpreta-
tions. The current understanding is still incomplete and
to a large extent based on assumptions yet to be vali-
dated. Therefore, the present study also interpreted how
the DCE MRI parameters we quantified correlated to the
underlying biology, by performing a quantitative analysis
of fluorescent immunohistochemistry (qIHC) of excised
tumor tissue.
Thus, this study aimed to characterize the vascular
responses to RT and ADT using an experimental,
androgen-sensitive PC model. Animals were subjected
to in vivo DCE MRI and analyzed with both semi-
quantitatively and by pharmacokinetic models. The animals’
tumors were excised immediately after MRI for quantita-
tive ex vivo analysis of tumor vascularization (9 F1), perfu-
sion (Hoechst 33342), and hypoxia (pimonidazole).
Materials and methods
Experimental tumor model
Tumors were generated by subcutaneous (s.c.) implant-
ation of (~2 mm)3 tumor tissue from the human,
androgen-sensitive CWR22 PC xenograft, together with
a 12.5 mg sustained-release testosterone pellet (Innova-
tive Research of America, Sarasota, FL), into adult male
Balb/c nude mice. These pellets ensure stable, human
serum testosterone levels and contribute to improved
recapitulation of androgen-regulated homeostasis [8].
Animal experiments were performed in accordance with
protocols approved by the institutional animal care and
use committee, in compliance with guidelines on animal
welfare of the Norwegian National Committee for
Animal Experiments. Tumor sizes were measured using
calipers from implantation until the end of the experiment.
Treatments and experimental groups
The study included two consecutive experiments with
untreated (Ctrl), irradiated (RT), androgen-deprived
(AD), and castration-resistant (CR) tumors. The CWR22
xenograft mimicks the clinical situation of PC disease
progression, by regressing after ADT, and showing sta-
bility during long-term ADT before recurrent CR tumor
growth is evident, a disease which presently is incurable
in the clinic. To allow tumor size-independent compari-
sons all analyzed tumors had diameters of 8 mm.
Firstly, animals in the Ctrl group (n = 4) were subjected
to DCE MRI when the tumor diameter reached 8 mm.
For the RT group (n = 6), tumors reaching 8 mm in
diameter were irradiated with a single dose of 15 Gy, fol-
lowed by DCE MRI 24 h later, a time-point selected
based on a previous study investigating radiation-
induced effects in the CWR22 xenograft [9]. Radiation
was delivered using a 60Co source (Mobaltron 80, TEM
Instruments, Crawley, UK), with a dose rate of 0.8 Gy/
min. Tumor irradiation was performed by placing the
tumors in the corners of a 10 × 10 cm radiation field,
keeping the animals’ bodies outside the field to minimize
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radiation dose deposition to normal tissues. ADT was
performed when the shortest tumor diameter reached
12 mm, by surgically castrating the animals and remov-
ing the testosterone pellet. One month post-castration
the tumor size was reduced to 8 mm in diameter, upon
which the animals were subjected to DCE MRI (n = 4).
Following MRI all tumors were excised and immediately
snap-frozen for qIHC.
Secondly, the experiment was repeated to analyze Ctrl
(n = 5), AD (n = 5), and CR (n = 5) tumors of identical
size as in the first experiment. All tumors were subjected
to DCE MRI, and blood sampling was performed for
measuring serum prostate-specific antigen (PSA) levels.
Radiation, castration, and MRI were performed under
anesthesia, after s.c. injections of a mixture of 2.4 mg/ml
tiletamine and 2.4 mg/ml zolazepam (Zoletil vet, Virbac
Laboratories, Carros, France), 3.8 mg/ml xylazine
(Narcoxyl vet, Roche, Basel, Switzerland), and 0.1 mg/ml
butorphanol (Torbugesic, Fort Dodge Laboratories,
Fort Dodge, IA), diluted 1:5 in sterile water, in doses
of 5 μl/g prior to radiation, and 7.5 μl/g before MRI
acquisitions and castration. Analgesia was provided to
castrated animals by s.c. injections of buprenorphine
(Temgesic, Schering-Plough, Brussels, Belgium) in a
dose of 0.1 mg/kg.
Prostate-specific antigen
Blood samples were withdrawn from the animals’
femoral veins immediately before euthanasia and tumor
excision. The samples coagulated before being centri-
fuged and frozen at −80°C until all samples were ana-
lyzed simultaneously. Serum PSA levels were measured
using the fluoroimmunometric AutoDELFIA ProStatus
PSA Free/Total kit (PerkinElmer Life and Analytical
Sciences, Wallac Oy, Turku, Finland).
DCE MRI acquisition and analysis
DCE MRI was acquired as previously described [10],
and analyzed using in-house developed software in IDL
(Interactive Data Language v6.2, Research Systems Inc.,
Boulder, CO), as illustrated in Figure 1. For the central
slice of each tumor, a region-of-interest (ROI) was manu-
ally traced in T1-weighted DCE MR images, excluding
surrounding skin and connective tissue. Firstly, semi-
quantitative analysis was performed. The time-dependent
relative signal intensity (RSI(t)) was calculated for each
image voxel using the equation RSI(t) = (SI(t) – SI(0))/SI
(0), where SI(0) refers to the pre-contrast signal intensity
and SI(t) the post-contrast signal intensity in the voxel at
time t. The semi-quantitative parameter area under the
RSI(t) curve (AUC(t)) was calculated for t= 1, 2, 3, 4, 5,
10, 15, and 20 min.
Secondly, pharmacokinetic analysis was performed
using the two-compartment Tofts model [11]. Signal
intensities were converted into contrast agent (CA) con-
centration (C(t)) by using the method of Hittmair [12].
The vascular input function (VIF) needed in Tofts mod-
eling has previously been established for our male mouse
strain: VIF = 3.57 e-(0.025)t + 1.45 e-(0.0074)t [10]. Using the
VIF parameters and the CA concentration curves, each
voxel was fitted to the Tofts model, allowing estimations
of the forward volume transfer constant of CA from
blood plasma into the EES, Ktrans (s-1), the backward
transfer constant from EES to blood plasma, kep (s
-1),
and the fractional distribution volume of CA, Ve (a. u.),
as derived from Ktrans/kep. When performing Tofts mod-
eling, the fit fails to converge for some voxels due to low
CA uptake or voxels providing negative values. These
unfitted voxels were set equal to 0 and included in
calculation of parametric tumor maps. The unfit frac-
tion; i.e. the sum of unfitted voxels versus the total
number of voxels within the tumor ROI, was monitored
to investigate the possible relation between this fraction
and tumor necrosis assessed in the tissue sections.
Immunohistochemistry
Sixty minutes prior to euthanasia, 80 mg/kg of pimoni-
dazole hydrochloride (1-[(2-hydroxy-3-piperidinyl)pro-
pyl]-2-nitroimidazole hydrochloride, Natural Pharmacia
International Inc., Burlington, MA, USA) in 0.5 ml saline
was injected intraperitoneally (i.p.) in the animals to de-
termine tumor hypoxia. Tumor perfusion was found by
i.v. injection of 15 mg/kg Hoechst 33342 (Sigma-Aldrich,
Oslo, Norway) in 0.1 ml saline 5 min before euthanasia.
Immediately after dissection, tumors were snap-frozen
in liquid nitrogen and stored at −80°C until being
shipped to the Department of Radiation Oncology, Rad-
boud University, Nijmegen Medical Center, Nijmegen,
The Netherlands, for staining and imaging. The central
slice of the tumor was cut before being stained and
scanned according to previously described procedures
[13], to obtain three spatially matched immunofluores-
cent images of tumor vascularization (9 F1; TCL image,
TNO, Delft, The Netherlands), tissue perfusion (Hoechst
33342), and hypoxia (pimonidazole).
Quantitative analysis of immunohistochemistry
Spatial maps of hypoxia, vessels, and perfused area were
created from immunofluorescent images. Firstly, hypoxic
regions were determined from pimonidazole stains using
MATLAB 7.0.1 (The MathWorks, Natick, MA). Differ-
ent methods were used due to differences in signal
intensity and image contrast between different batches.
For nine cases: (a) the image was digitally filtered to cor-
rect for unequal illumination in each tile, (b) a Gaussian
blur was applied to smooth the image (σ= 8 px), and (c)
the threshold was set to the mean of the 5th and 95th
percentile intensity value. For six cases the threshold
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was set to 0.3 × 95th intensity percentile, and in one case
the threshold was set manually. Secondly, vessels were
manually delineated in 9 F1 stains. Thirdly, perfusion
was manually segmented using local and/or global
thresholds in Hoechst stains. The following regions were
manually delineated based on a combination of stains:
(a) gross tumor region, (b) artifacts, (c) necrosis; regions
with a strong background signal from 9 F1 and a low sig-
nal from pimonidazole, (d) other tissue; tumor regions
with markedly different texture in 9 F1 and pimonidazole
stains, and a defined transition to viable tumor regions.
Two additional tumor regions were defined: (e) net tumor;
gross tumor excluding artifacts, and (f) viable tumor; net
tumor excluding necrosis and other tissue. The necrotic
fraction (NF) was defined as necrotic area/net tumor area.
A vessel was defined as an independent contiguous 8-
connected region in the vessel map, and lumens were
considered part of the vessel. The following vessel para-
meters were extracted: total number of vessels (VN),
vessel density (VD) as VN/viable tumor area, vascular
area fraction (VF) as vascular area/viable tumor area,
and mean vessel size (VS).
A vessel was considered to be perfused if it was less
than 20 μm away from a perfusion stain with at least
10% of its area. The following perfusion parameters were
extracted: perfusion stain fraction (PF) as perfusion stain
area/viable tumor area, and perfused vessel fraction
(PVF) as number of perfused vessels/VN.
These parameters measured the degree of hypoxia:
hypoxic fraction (HF) as hypoxic area/viable tumor area,
and mean distance from hypoxic pixels to nearest vessel
(DHV). Since pimonidazole staining intensity could not
be converted to oxygen pressure (pO2), the exact bound-
ary between hypoxia and normoxia cannot be decided;
HF and DHV are considered to be estimates propor-
tional to true values. The theoretical normoxic frac-
tion was calculated based on the assumption that all
(perfused) vessels supply oxygen and that the diffusion
range of oxygen is 70 μm: fraction of viable tumor
tissue < 70 μm away from a vessel (VF70V).
Estimation of acute hypoxia was based on the follow-
ing assumptions: (a) since transport of Hoechst requires
a functional and oxygenated vascular network, areas
with perfusion staining were considered functional after
Hoechst injection; (b) areas of hypoxia staining were
considered to reflect hypoxia after pimonidazole injec-
tion. By assuming that the metabolic activity was suffi-
ciently low to not affect the diffusion distance of oxygen,
it was further assumed that the diffusion distance
of oxygen was longer than the diffusion distance of
Hoechst, and thus, that the amount of pimonidazole
staining within a 50 μm distance from perfusion stains
was proportional to the amount of acute hypoxia. The
proportion of the total HF that was acute was named
“acute hypoxia score” (AHS). The remaining proportion
is thus representing chronic hypoxia (= 1 – AHS).
The manual delineations and thresholds were performed
in Gimp 2.6.4 (www.gimp.org), and quantitative analysis in
an in-house program written in Python 2.6.6 (www.python.
org), with the scipy extension (www.scipy.org).
Statistics
Statistical analysis was performed using PASW Statistics
18.0 (IBM, Somers, NY). Differences were analyzed using
Figure 1 Dynamic contrast-enhanced MRI of experimental prostate cancer. Following dynamic contrast-enhanced (DCE) MRI the tumors
were traced in the T1-weighted images. Firstly, semi-quantitative analysis was performed on the time-dependent relative signal intensity (RSI(t))
curves, by calculating the area under the RSI curve (AUC(t)), of each tumor voxel, for different time-points. Secondly, pharmacokinetic analysis
was performed using the Tofts model, producing parametric tumor maps of Ktrans, kep, and Ve. Examples of parametric tumor maps are shown
to the right.
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two-sided t-tests and correlations assessed by Pearson’s
correlations (r). A significance level of 5% was used.
Results
Assessment of response to radiotherapy and
androgen-deprivation therapy by quantitative
immunohistochemistry
To characterize the response to RT and ADT, qIHC was
performed. Matching sets of images of tumor hypoxia
(pimonidazole), endothelium (9 F1), and perfusion
(Hoechst 33342) (Figures 2A–C), as well as a combined
image (Figure 2D), were obtained. Corresponding maps
of the tumor-specific features (Figures 2E–H) were
extracted and used in qIHC.
Figure 3 shows the results summarized per experimen-
tal group. Compared to Ctrl tumors, AD tumors pre-
sented significant increases in several vascular qIHC
parameters; a 3.5-fold increase in VN (p= 0.012)
(Figure 3A), a 5.1-fold increase in VD (p= 0.009)
(Figure 3B), and a 3.2-fold increase in VF (p= 0.003)
(Figure 3D). The viable tissue was located closer to the
vasculature in AD tumors compared to in Ctrl tumors,
as reflected by a 1.7-fold increase in VF70V (p < 0.001)
(Figure 3G). Also the hypoxic stains were closer to ves-
sels in AD tumors, reflected by DHV being 0.7-fold
decreased (p= 0.002) (Figure 3H) compared to Ctrl
tumors. AD induced an insignificant decrease in VS
(Figure 3C) and NF (Figure 3I). The changes in PF
(Figure 3E) and VPF (Figure 3F) in AD tumors com-
pared to Ctrl tumors were statistically insignificant;
yet they indicate that tumors regressing in size after
ADT acquire more vessels at a higher density, and
remain equally perfused and highly functional.
Following RT, the sole significant vascular change
compared to Ctrl tumors was the 0.4-fold decrease in PF
(p= 0.031) (Figure 3E). The changes in VN (Figure 3A),
VD (Figure 3B), VS (Figure 3C), VF (Figure 3D), DHV
(Figure 3H), and NF (Figure 3I) were insignificant. The
other parameters (VPF,VF70V) remained unchanged.
Generally, these results unveiled minor radiation-
induced effects on tumor vasculature, whereas AD tumors
showed significantly increased tumor vascularization.
A
B
C
D
E
F
G
H
Hypoxia
image
(pimonidazole)
spaMsegamI
Endothelium
image
(9F1)
Perfusion
image
(Hoechst
33342)
Combined
image
Hypoxia
map
Endothelium
map
Perfusion
map
Combined
map
Figure 2 Fluorescent immunohistochemical images and maps. Tumors were triple-stained with fluorescent immunohistochemical markers of
hypoxia (pimonidazole), endothelium (9 F1), and perfusion (Hoechst 33342), to produce images of hypoxia (A), endothelium (B), perfusion (C),
and a combined image (D). Corresponding maps were extracted and used in the quantitative analysis (E-G). Composite map where artefacts and
necrosis, which were excluded from the measurements, are shown in white (H).
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Figure 3 (See legend on next page.)
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Compared to the Ctrl cohort, AD tumors developed many
small vessels covering a significantly larger fraction of the
total tumor area. This increased tumor vascularization
amongst AD tumors is visualized by perfusion and endo-
thelium maps in Figure 4.
The HF did not differ significantly between the groups
(Figure 3J). However, independent of HF the estimated
AHS was 2.5-fold higher (p= 0.002) in AD tumors com-
pared to in Ctrl tumors, whereas RT tumors only
showed an insignificant increase (Figure 3K).
Assessment of response to radiotherapy and androgen-
deprivation therapy by dynamic contrast-enhanced MRI
Figures 5A-D show that inter-group differences in AUC
values were most evident at initial time-points and less
pronounced at later time-points. Compared to Ctrl
tumors, RT induced insignificant changes in AUC
values, whereas AD tumors presented significantly
higher AUC values than Ctrl tumors at all analyzed
time-points, with the largest increase at the initial time-
point, AUC 1 min, being 2.8-fold (p = 0.016). The
AUC values remained high in AD tumors during the
initial time-points before gradually decreasing relative to
Ctrl tumors, the difference being 2.5-fold at 2 min
(p= 0.007), 2.3-fold at 3 min (p= 0.004), 2.0-fold at 4 min
(p= 0.002), 2.0-fold at 5 min (p= 0.002), 1.7-fold at
10 min (p= 0.012), 1.6-fold at 15 min (p= 0.020) and 1.5-
fold at 20 min (p= 0.034).
In Figures 5E-G, intergroup differences in Tofts phar-
macokinetic parameters are shown. Compared to Ctrl
tumors, RT induced a 0.5-fold reduction in Ktrans,
whereas a significant 1.8-fold increase was unveiled in
(See figure on previous page.)
Figure 3 Quantitative immunohistochemical analysis. Intergroup differences in parameters from quantitative immunohistochemical analysis
of triple-stained tumor tissue sections (9 F1; endothelium, Hoechst 33342; perfusion, pimonidazole; hypoxia) from untreated (Ctrl), irradiated (RT),
and androgen-deprived (AD) prostate carcinoma (PC) xenografts, presented as mean and s.e.m. per group. Significant differences (p< 0.05)
compared to Ctrl tumors are indicated with a *.
Perfusion
+
endothelium 
map
Perfusion
map
Endothelium
map
Androgen-exposed (Ctrl) Androgen-deprived (AD)
A
B
C
D
E
F
Figure 4 Tumor vascularization in androgen-deprived versus untreated tumors. Increased tumor vascularization in an androgen-deprived
(AD) tumor (left column) compared to untreated (Ctrl) tumor (right column) visualized by combined perfusion and endothelium maps (A and D,
respectively), and separate maps of perfusion (B and E, respectively) and endothelium (C and F, respectively).
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AD tumors (p= 0.041) (Figure 5E). For kep, RT tumors
showed a 0.8-fold reduction (p= 0.002), in contrast to a
1.5-fold increase in AD tumors, when compared to Ctrl
tumors (Figure 5F). Large intra-group differences in Ve
resulted in insignificant changes in both RT and AD
tumors (Figure 5G). The unfit fraction showed a 3.0-fold
increase (p= 0.026) in RT tumors, and a 0.6-fold reduc-
tion (p= 0.046) in AD tumors, compared to Ctrl tumors
(Figure 5H).
Correlations between quantitative immunohistochemistry
and dynamic contrast-enhanced MRI
Figure 6 shows resulting Pearson correlation coefficients
(r) from correlating parameters from DCE MRI and
qIHC. Initial AUC values (< 4 min) correlated very
strongly and positively (r = 0.8–1.0) to VD and VF,
whereas correlations at later time-points were less pro-
nounced (r= 0.6–0.8). The Tofts parameters Ktrans and
kep also correlated significantly to VD, although not as
strong as the AUC values (r= 0.6–0.8). Tumor perfusion,
as reflected by PF, was weakly correlated to AUC values
(r= 0.4–0.6). Of note, VS correlated only insignificantly,
and negatively, to all AUC values. NF was negatively cor-
related to initial AUC values (r= 0.4–0.6). The overall
HF did not correlate to any AUC parameter, but DHV
correlated negatively (r = 0.6–0.8) to all AUC values
obtained from 1 min to 10 min. The AHS fraction
correlated positively and very strongly to NF (r= 0.85).
Tofts parameters correlated poorly to HF, but kep was
strongly positively correlated to AHS (r = 0.72).
Vascular changes occurring in the development of
castration-resistant disease
The large vascular changes identified in AD tumors
motivated a repeated experiment including tumors
re-growing in the CR disease state. Figure 7A visualizes
the development of CR tumors 5.4 ± 0.4 months after
ADT by castration. Figure 7B shows the expression of
serum PSA in blood samples from animals with Ctrl
tumors, AD tumors, and CR tumors. The reduction in
serum PSA from Ctrl to AD was significant (p= 0.032),
whereas the rise in PSA from AD to CR was close
to significant (p= 0.085). The DCE MRI parameters
best reflecting tumor vascularization, as identified from
Figure 6, were calculated from the Ctrl, AD, and CR
tumors. In Figure 7C, an increase in AUC 1 min and
AUC 2 min from Ctrl tumors to AD tumors was again
seen (1.8-fold increase, p= 0.011 and 1.7-fold increase,
p= 0.025, respectively). The transition from AD tumors
to CR tumors unveiled a further increase in tumor
vascularization, as seen by the 1.4-fold increase
(p= 0.010) in AUC 1 min and a further 1.3-fold increase
(p < 0.001) in AUC 2 min. Also the Tofts parameters in
Figure 7D showed similar pattern; a 1.3-fold increase
Figure 5 Semi-quantitative and pharmacokinetic analysis of dynamic contrast-enhanced MRI. Both semi-quantitative and pharmacokinetic
DCE MRI parameters unveiled increased vascularization in androgen-deprived (AD) tumors. Intergroup differences between untreated (Ctrl),
irradiated (RT), and androgen-deprived (AD) prostate carcinoma (PC) xenografts for the semi-quantitative parameter area under the relative signal
intensity curve (AUC) (a.u.) for 1 min (A), 5 min (B), 10 min (C), and 20 min (D), and Tofts kinetic model parameters Ktrans (s-1) (E), kep (s
-1) (F), and
Ve (a.u.) (G), in addition to the fraction of unfitted voxels (H), summarized as mean and s.e.m. per group. Significant differences (p< 0.05)
compared to Ctrl tumors are indicated with a *.
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(p=0.012) in Ktrans from Ctrl tumors to AD tumors, and a
further 1.4-fold increase (p=0.043) from AD tumors to CR
tumors, whereas kep showed an insignificant change from
Ctrl tumors to AD tumors, followed by a significant 1.6-
fold increase (p=0.007) from AD tumors to CR tumors.
Discussion
In the present study the vascular responses to RT and
ADT in experimental PC were characterized by qIHC
and DCE MRI. Our key findings were the increased
tumor vascularization following ADT, and the identifica-
tion of a set of DCE MRI parameters non-invasively
reflecting these vascular changes.
The xenograft used was originally derived from a
patient’s primary, androgen-sensitive PC that later devel-
oped metastatic disease [14], thus being a clinically rele-
vant model of advanced PC. This model enables
investigations of the response to different interventions,
in particular ADT, since this xenograft regresses after
castration and shows stability before recurrent CR
growth is evident, as also experimentally verified in this
study (Figures 7A-B).
By qIHC an increased tumor vascularization was
detected in AD tumors one month post-castration, com-
pared to Ctrl tumors. This was reflected by the increased
VN,VD and VF, although VS was smaller (Figure 3). Fur-
ther, the vessels appeared to be highly functional despite
their smaller size. This seems possible since the vessels
were equally, or even more perfused as compared to Ctrl
tumors, as reflected by unchanged VPF and the clear
tendency of increased PF (Figure 3). Together, these
findings are consistent with tumor neovascularization
following ADT. We found a small, but insignificant, in-
crease in HF. However, more interestingly the DHV was
significantly shorter in AD tumors compared to in Ctrl
tumors, which encouraged a further analysis of whether
ADT had altered the ratio of acute versus chronic hyp-
oxia independently of the total HF. For this purpose we
estimated AHS (Figure 3K), revealing increased acute
hypoxia, and thus less chronic hypoxia, in AD tumors
compared to Ctrl tumors.
The mechanisms responsible for the ADT-induced
changes in tumor vascularization and hypoxia are pre-
sumably caused by a complex interplay of different pro-
cesses. First, a substantial increase in vessel formation
may be expected during unperturbed growth from
8 mm (the diameter of tumors in Ctrl tumors) to 12 mm
(the diameter of tumors at the time of castration). Fol-
lowing castration, volume reduction caused by death of
androgen-sensitive, endothelial cells occur, likely result-
ing in vessel shrinkage. However, our results indicate a
very high number of functional vessels with capability to
transport blood, as reflected by the preserved tumor per-
fusion. Moreover, we observed an increased VD in AD
tumors. One month after castration the tumor volume
regressed by approximately a factor 3 (from a tumor
volume of 864 mm3 (diameter of 12 mm) to a tumor
volume of 256 mm3 (diameter of 8 mm)). A corre-
sponding 3-fold increase in VD would thus be ex-
pected if the number of vessels remained identically as
pre-ADT. However, the observed increase in VD was
of a factor 5, and hence, a high number of vessels with
smaller VS may not be explained by ADT-induced vol-
ume reductions alone. It has previously been shown
that an immediate effect of ADT involves induction of
acute hypoxia, including activation and stabilization of
the hypoxia-inducible factor 1α (HIF-1α), and subse-
quent expression of HIF-1α target genes, such as the
vascular endothelial growth factor (VEGF) [15-17], a
key player involved in tumor neovascularization. Given
that this occurs, formation of large numbers of small,
new vessels may be expected. Such a neovascularization
may explain the significant changes detected in vascular
and perfusion-related qIHC parameters.
The AHS increased in AD tumors compared to in Ctrl
tumors. Since perfusion qIHC parameters increased in
Parameter VS VD VF PF DHV NF HF AHS 
AUC 1 min      +  
AUC 2 min      +  
AUC 3 min     +  
AUC 4 min     +  
AUC 5 min     +  
AUC 10 min   +  +  
AUC 15 min   + + + 
AUC 20 min   + + + 
Parameter VS VD VF PF DHV NF HF AHS 
Ktrans   + +   + + 
kep        
Ve + + + + + 
Unfit fraction       
A  Semi-quantitative analysis: 
B   Tofts kinetic analysis: 
Color scale for Pearson correlation coefficients: 
    
      
1.0 - 0.8 0.8 - 0.6 0.6 - 0.4 0.4 - 0.2 0.2 - 0.0 
Figure 6 Correlations between parameters from dynamic
contrast-enhanced MRI and quantitative
immunohistochemistry. Correlations between DCE MRI parameters
from (A) semi-quantitative and (B) Tofts kinetic analysis, and qIHC
parameters. Color labeling reflects correlation strength (Pearson
correlation coefficients), as indicated in the color scale (top). Positive
and negative correlations are indicated with + and –, respectively,
and encircled + and – denotes significant correlations (p< 0.05).
Abbreviations: AUC; area under the relative signal intensity (RSI)
curve, VS; mean vessel size (μm2), VD; vessel density (number of
vessels/mm2), VF; vessel area fraction, PF; perfused area fraction, DHV;
distance from hypoxia to vessels (μm), NF; necrotic fraction, HF;
hypoxic fraction, AHS; acute hypoxia score\.
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AD tumors compared to in Ctrl tumors, it is not likely
that the vessels are perfusion-limited or occluded, as is
expected by the increased presence of acute hypoxia.
Yet, small fluctuations in blood flow may result in tem-
porary occlusions and transient hypoxia. However, such
occlusions do not seem to severely have affected tumor
vascularization and perfusion in AD tumors. In fact, it
appears as if the vascular function in AD tumors is
superior to in Ctrl tumors. It could be that the increase
in acute hypoxia is followed by a reoxygenation of the
tumor tissue. If extrapolating to the clinical situation,
such a reoxygenation hypothesis may provide a possible
explanation as to why neoadjuvant ADT combined with
RT has been shown to improve treatment outcome and
Figure 7 Vascular changes in the transition from untreated (Ctrl), via androgen-deprived (AD), to castration-resistant (CR) disease.
Response to androgen-deprivation therapy (ADT) on tumor volumes, showing that CR tumors developed 5.4 ± 0.4 months after ADT (A).
Response to ADT on serum prostate-specific antigen (PSA) expression measured in blood samples withdrawn from the animals (B). The vascular
parameters AUC 1 min and AUC 2 min calculated from semi-quantitative analysis of DCE MRI (C). The vascular parameters Ktrans and kep derived
from Tofts pharmacokinetic modeling of DCE MRI (D). Significant differences (p< 0.05) compared to Ctrl tumors are indicated with a *.
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patient survival [2,3]. However, it has also been shown
that reoxygenation after acute hypoxia contributes to
increased genomic instability, and thus disease progres-
sion [18], including increased formation of metastasis
[19,20].
The increased vascularization following ADT may also
relate to development of a more aggressive disease, and
hence, represent a step in the transformation into CR
disease. Clinical studies in PC have previously connected
microvessel density to poor survival [21-23]. When we
repeated the experiment and extended it to also include
CR tumors, where the serum PSA levels increased and
renewed growth appeared, we detected an even further
increased tumor vascularization compared to both Ctrl
tumors and AD tumors (Figure 7C and D). Highly vas-
cularized tumors are usually well oxygenated and sensi-
tive to radiation. These tumors may, paradoxically, have
enhanced activation of angiogenic factors normally
found in hypoxic, radiation resistant tumors and in
tumors associated with a poor prognosis [24]. Both for
breast cancer and colorectal cancer correlations between
enhanced expression of angiogenic factors and poorer
prognosis and shorter disease-free survival have been
shown [25,26]. Moreover, highly angiogenic tumors are
more likely to develop metastatic disease as the prob-
ability of secreting tumor cells into the circulation is
higher [27].
Human studies characterizing vascular effects follow-
ing ADT are limited. Animal studies have shown that
immediate responses to ADT involve blood flow reduc-
tions and vascular degenerations [28-31]. The recent
study by Godoy et al. [6] shows vascular recovery after
ADT, as demonstrated by increased microvessel density
and vascular lumen diameter. The difference in the
study by Godoy et al. to previous studies is that they not
only characterized the immediate effect of ADT on
tumor vasculature, but prolonged their post-ADT inves-
tigation period. Thus, these results indicate that ADT
induces an immediate, transient degeneration of tumor
vascularization before androgen-sensitive, endothelial
cells develop alternative mechanisms to reproduce the
vascular network in the absence of androgens. A recent
DCE MRI study in PC patients oppositely demonstrated
decreased Ktrans after 1 and 3 months of ADT [32]. One
explanation for the different results may be related to
the timing of the measurements. The clinical study may
comply with the preclinical results of initial vascular
degenerations. Our results, obtained 1 month post-ADT,
anticipated to correspond to about 5 months in humans
after accounting for the five times faster metabolism
in mice, may reflect a later disease stage with vascular
recovery, and comply with the results by Godoy et al.
[6]. The challenges with translating time-dependent
treatment effects in xenografts to humans indicate that
studies characterizing the long-term effects of ADT on
tumor vascularization should be further investigated in
the clinical setting. One approach could be to perform
DCE MRI also at later disease stages after ADT, prefer-
ably as repeated measurements in the same patients.
The results from qIHC following RT showed results
being consistent with previous findings. RT did not
result in substantial effects on VD and VF 24 h post-
irradiation, only an insignificant increase in vessel size
VS was found. The increased VS may relate to radiation-
induced dilatation of tumor capillaries, as has been
previously shown [24,33]. Further, RT resulted in a sig-
nificant decrease in PF, as also shown by others [34]; this
is likely attributed to the formation of radiation-induced
edemas and capillary injuries. Successful RT results in
irreversible DNA damages, which are in accordance with
the increased NF in the RT tumors. Moreover, it is also
previously shown that vascular alterations after RT can
be detected by DCE MRI [35].
Vascular qIHC parameters, like VD and VF, correl-
ated strongly to AUC values from the initial time-points
(Figure 6). Moreover, AUC values were negatively corre-
lated to DHV. This may be related to the higher fraction
of viable cells, as reflected by the VF70V parameter,
close to the vessels in tumors with short DHV. Applying
the Tofts kinetic model, the kep parameter improved the
correlation to VS compared to using AUC values. VD
was also positively correlated to the Tofts parameters,
albeit less than the AUC values. In summary, the corre-
lations between DCE MRI parameters and vascular
qIHC parameters showed that AUC values reflect VD
and VF strongly, whereas estimation of VS from DCE
MRI requires the use of the Tofts kinetic model. Since
parameters from the Tofts model previously have shown
to be indirectly related to tumor hypoxia [7,36], the poor
correlations between HF and all DCE MRI parameters
were surprising. It should be noted that the HF was not
found to correlate to other qIHC parameters either, nor
differentiate treatment groups in the t-test. One possible
reason may be that the analyzed tumors, with a few
exceptions, showed relatively similar HF, and hence, the
spread in the data were too low to resolve any such cor-
relation. By estimating AHS (Figure 3K), substantially
higher and significantly positive correlations to several
DCE MRI parameters were found (Figure 6).
The NF was strongly correlated with the unfit fraction
from the Tofts model, i.e. the voxels with low contrast
enhancement. Bradley et al. [37] and Galbraith et al. [38],
as well as our own previous study [10], have revealed
similar correlations, providing support for the unfit frac-
tion as a non-invasive biomarker of tumor necrosis.
In this study, the potential of DCE MRI to provide
non-invasive biomarkers of tumor vascularization was
assessed. After the recognition of the importance of the
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condition of the tumor vasculature, including tumor hyp-
oxia, for treatment response and disease outcome in on-
cology [39,40], several functional imaging modalities have
been investigated for their ability to provide such non-
invasive biomarkers. In addition to DCE MRI and
diffusion-weighted (DW) MRI, positron emission tomog-
raphy (PET), dynamic computed tomography (CT), and
ultrasound Doppler imaging, have been proposed as
promising modalities. The benefits with MRI include that
it is a wide-spread, clinically established modality, also in
advanced PC, and hence, any new sequences, such as
DCE MRI, may easily be added. Moreover, compared to
PET and CT, MRI benefits from the avoidance of ionizing
radiation exposure, as well as being more cost-effective.
In conclusion, DCE MRI non-invasively detected an
increased and highly functional vascular network in
experimental prostate tumors after ADT, which was
confirmed by qIHC. The findings encourage further stud-
ies into whether these vascular changes are beneficial for
combined RT, or if treatment with anti-angiogenic ther-
apy or vascular disrupting agents may be a strategy to
improve the therapeutic efficacy of ADT in advanced PC.
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